Advertisement


Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab

2024 ASCO Annual Meeting

Advertisement

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (Abstract TPS7089).  



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
[Inaudible 00:00:08] is a standard of care option for patients with CLL, SLL, who have relapsed after at least one line of prior therapy. However, there is an unmet need for more effective treatments. Bruton tyrosine kinase, BTK, plays an important role in the pathogenesis of CLL. Nemtabrutinib is a BTK inhibitor that targets both wild-type and C-481 mutant forms of BTK, in the ongoing BELLWAVE-001 study, nemtabrutinib demonstrates manageable safety and durable anti-tumor activity in patients with refractory relapse, CLL, SLL, with and without C-481 mutations. The randomized open-label phase III BELLWAVE zero-tense study is designed to evaluate the efficacy and safety of nemtabrutinib plus venetoclax versus VR as a second line or later treatment for patients with RR CLL, SLL. Eligible patients are aged more than 18 years with active refractory relapse CLL, SLL after at least one line on prior therapy per IW-CLL 2018 criteria, and equal performance status of zero to two approximately 720 patients will be enrolled in two parts. Part one is an open-label, non-randomized dose escalation and confirmation phase to evaluate safety, and determine the optimal dose of nemtabrutinib plus venetoclax. Part one will enroll 30 patients to establish the dose of nemtabrutinib, using a modified toxicity probability interval design. Patients will receive nemtabrutinib at two dose levels. 45 milligram per day parallel Q-day, starting dose. Escalating to six five milligram parallel Q-day for 28 days, followed by nemtabrutinib plus venetoclax ramp up over four weeks. Part two is an open-label parallel group randomized phase comparing the efficacy and safety of nemtabrutinib plus venetoclax with VR. In part two, approximately 690 patients will be randomly assigned one-to-one to receive either nemtabrutinib at recommended dose for 28 days, followed by the nemtabrutinib plus venetoclax, or venetoclax plus rituximab. Study treatment will continue for approximately two years, or until an acceptable toxicity, disease progression, or other discontinuation criteria are met. Randomization will be certified by BTKC-481 mutation status, geographic region, and risk group. The primary endpoint for part two is progression free survival by Blinded Independent Central Review, BICR, per IWCLL 2018 criteria. Secondary endpoints for part two are: Undetectable, minimal residual disease in bone marrow at month 14 by central laboratory assessment, objective response rate and duration of response by BICR per IWCLL 2018 criteria, Overall survival and safety. Exploratory endpoints are overall response rate, including partial response with lymphocytosis, pharmacokinetics, and heart-related quality of life. Recruitment is ongoing.

Related Videos

Prostate Cancer

Alicia Morgans, MD, MPH, and Karim Fizazi, MD, PhD, on Prostate Cancer: Study Findings on Health-Related Quality of Life and Pain

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).

Breast Cancer

Denise A. Yardley, MD, on Early Breast Cancer: Findings From the NATALEE Trial on Patients With Node-Negative Disease

Denise A. Yardley, MD, of the Sarah Cannon Research Institute, discusses the NATALEE trial, which assessed ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with hormone receptor–positive/HER2-negative early breast cancer at increased risk of recurrence, including patients with node-negative disease, and showed a benefit in invasive disease–free survival (Abstract 512).

Lymphoma

Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).

Pancreatic Cancer

Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy

Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for early-stage disease (Abstract 107).

Bladder Cancer

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan

Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss clinical outcomes of sacituzumab govitecan-hziy after prior exposure to enfortumab vedotin-ejfv in patients with metastatic urothelial carcinoma, as well as the safety and efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing bladder tumors (Abstracts 4502 and 4509).

Advertisement

Advertisement




Advertisement